Glassware combines safety and performance
KIMAX GL 45 storage/media bottles are made with Type 1 Class A borosilicate glass
The bottles are available with linerless, autoclavable (up to 140°C) polypropylene GL 45 caps with an internal seal. For easy identification, they can be specified with blue, white or orange caps.
Other caps available include a red PBT (polybutyleneterephthalate) cap with PTFE/silicone liner (up to 180°C) offering resistance to solvents and acids.
A blue vented cap (up to 140°C) is also available for equalising pressure during autoclaving. An extra wide neck opening facilitates access, and replaceable polypropylene pour rings minimise drips while pouring.
KIMAX storage/media bottles feature permanent, white enamel graduations and marking spots. For enhanced safety, the bottles may be treated with KimCote, an ultra-clear coating that is applied to the exterior of laboratory glassware to resist breakage and contain leaking.
For light-sensitive compounds, Kimble Chase offers RAY-SORB treated glassware.
Kimble Chase Life Science and Research Products, based in Vineland, New Jersey, was formed in July 2007 through a joint venture between specific operations of Thermo Fisher Scientific and Gerresheimer Glass. The company designs and manufactures reusable, disposable and specialist glassware for laboratories across a range of industries, including pharmaceuticals and life sciences.
You may also like
Trending Articles
You may also like
Manufacturing
Lonza appoints Hans Trees as Global Head of Communications
Hans Trees will join Lonza as Global Head of Communications, Senior Vice President and Member of the Extended Executive Committee, effective 1 September 2026. Hans combines deep industry experience with a strong track record in stakeholder engagement, most recently serving as Global Head of External Engagement at Roche
Manufacturing
AlzeCure licenses Alzheimer’s candidate ACD680 to Lilly in deal worth up to $1bn
AlzeCure Pharma has entered a global licensing and collaboration agreement with Eli Lilly for its Alzheimer's disease candidate ACD680, securing a $10m upfront payment and potential milestone payments exceeding $1bn
Manufacturing
Safety in pharmaceutical manufacturing: why a trusted partner makes all the difference
By taking a three-tiered approach to protecting patients and personnel and ensuring plant compliance, GEA adopts a consultative approach to helping its customers navigate the responsibilities of pharmaceutical manufacturing safety with confidence